Research into pain: real-patient data
According to Dr. Mikael Kowal, research coordinator at Bedrocan, this is a unique retrospective study: “It is not often that researchers have access to very solid real-patient data on difficult-to-treat chronic pain patients which are using Bedrocan products.”
The aim of the study is to assess the efficacy and tolerability of medicinal cannabis in patients with chronic pain who do not respond adequately to conventional medications.
Among other things, it is examined whether the current conventional pain medication, like opioids, and associated side-effects were reduced after the start of adjunctive medicinal cannabis.
Knowledge about the efficacy and tolerability of cannabinoids, the active substances in cannabis, for medicinal treatment is limited so far. The researchers hope to identify potential indicators of evidence that cannabis can be used as an adjunctive therapy with the aim of reducing pain significantly and, as a result, improving the patients’ quality of life.